Caroline Nitschmann, MD
Gynecologic Oncology · Burlington, MANPI 1538483003
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,338 of the $2,572 with a category attached, or 90.9%. Medtronic accounts for 92.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,244 and has fallen 89.1% since, to $136 in 2025.
Across 8 payments — averaging $321.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Intuitive Surgical$114
- Bayer$33
- Eisai Inc.$22
- Seagen Inc.$21
Across 2 payments — averaging $8692.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
What the payments were for
- Consulting fees$2,33891%
- Travel & lodging$442%
- Food & beverage$763%
- Education$1144%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $2,382 |
| Intuitive Surgical | 1 | $114 |
| Bayer | 1 | $33 |
| Eisai Inc. | 1 | $22 |
| Seagen Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,572 in reported general payments places this provider in the 80th percentile of 32 gynecologic oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 14 | $157 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Burlington
- Valena WrightBurlington$2K
- Amy BregarBoston$36K
- Whitfield GrowdonBoston$27K
- Alexander MelamedBoston$5K
- Tashanna MyersSpringfield$4K
- Sarah ParaghamianBoston$3K
- Michael MutoBoston$3K
- Taymaa MayBoston$2K
- Larissa MatteiWorcester$2K
- Jessica St LaurentBoston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.